Source:http://linkedlifedata.com/resource/pubmed/id/12492577
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2002-12-20
|
pubmed:abstractText |
Acute myeloid leukaemia (AML) with trilineage dysplasia (AML/TLD) is de novo AML recognized by the morphological dysplasia of three mature cell lines in the presence of leukaemic blasts. We studied the karyotypes of AML/TLD of patients with de novo AML, except for those with the French-American-British classification M3, who were enrolled onto the Japan Adult Leukaemia Study Group (JALSG)-AML 92 trial. Morphological and cytogenetic analyses were performed in 559 patients and TLD phenotype was found in 155 patients (27.7%). The 511 patients with informative morphological and cytogenetic data were classified into three groups according to karyotype: favourable, intermediate and adverse risk groups (92, 375 and 44 patients respectively). Normal karyotype was the most frequent as a total, and among both the non-TLD and TLD patients (164 patients 45.3% and 78 patients 52.7% respectively). All but one patient with AML/TLD was classified into the intermediate or adverse cytogenetic risk group. TLD phenotype was associated with lower remission rate and shorter overall survival but it did not influence disease-free survival. Although we did not find any specific cytogenetic abnormalities for AML/TLD, the rarity of favourable karyotypes among TLD patients indicates the biological difference between AML/TLD and AML/non-TLD.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0007-1048
|
pubmed:author |
pubmed-author:EmiNobuhikoN,
pubmed-author:Japan Adult Leukaemia Study Group,
pubmed-author:KobayashiTohruT,
pubmed-author:KuriyamaKazutakaK,
pubmed-author:MatsuoTatsukiT,
pubmed-author:MatsushimaTakafumiT,
pubmed-author:MiyawakiShuichiS,
pubmed-author:MiyazakiYasushiY,
pubmed-author:OhnoRyuzoR,
pubmed-author:OhtakeShigekiS,
pubmed-author:SakamakiHisashiH,
pubmed-author:ShinagawaKatsujiK,
pubmed-author:TomonagaMasaoM
|
pubmed:issnType |
Print
|
pubmed:volume |
120
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
56-62
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12492577-Acute Disease,
pubmed-meshheading:12492577-Adult,
pubmed-meshheading:12492577-Chi-Square Distribution,
pubmed-meshheading:12492577-Chromosome Deletion,
pubmed-meshheading:12492577-Chromosomes, Human, Pair 5,
pubmed-meshheading:12492577-Chromosomes, Human, Pair 7,
pubmed-meshheading:12492577-Disease-Free Survival,
pubmed-meshheading:12492577-Humans,
pubmed-meshheading:12492577-Japan,
pubmed-meshheading:12492577-Karyotyping,
pubmed-meshheading:12492577-Leukemia, Myeloid,
pubmed-meshheading:12492577-Middle Aged,
pubmed-meshheading:12492577-Multivariate Analysis,
pubmed-meshheading:12492577-Remission Induction,
pubmed-meshheading:12492577-Risk Factors,
pubmed-meshheading:12492577-Survival Rate
|
pubmed:year |
2003
|
pubmed:articleTitle |
Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study.
|
pubmed:affiliation |
Department of Haematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan. y-miyaza@med.nagasaki-u.ac.jp
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|